Abstract
The analysis of contemporary literature bears evidence that the development of therapeutics intended for optimum formation, preservation and restoration of human symbiotic microbiota and their practical implementation are among the critical ways of preventive and regenerative medicine development. On the one hand, search is ongoing for new application targets of traditional probiotics made on the base of live probiotic strains and their detailed analysis, on the other hand, biologically active microbial molecules or their complexes are being isolated and identified which determine their application targets, efficiency and possible negative consequences of using these probiotics. New potential probiotic strains capable of modifying microelement, antioxidant, anti-inflammatory, psychic statuses, epigenotype, quorum-sensing signaling are selected among both dominant microorganism species and among species represented on the skin and mucosa in low amounts (Shenderov 2014b). Supposedly, knowing the range and concentration of low molecular weight biologically active compounds formed by known or potential probiotic strains will help construct new effective metabiotics and set their optimum frequency, doses and method of administration. The selected strains of human origin with unique functional or biochemical activity can become perspective starter cultures for large-scale biotechnological production of microbial bioactive special-purpose substances. Their use as metabiotics in their own right or as fortifiers of known traditional probiotics, dietary supplements and functional foods will help develop and implement more efficient microecological products for symbiotic microbiota reservation and restoration in the majority of the population, in specific population groups and in individuals. It should also be remembered that beneficial effects of the prospective metabiotics depend to a great degree on the composition of the growth medium, time and conditions for initial starter culture incubation, methods of lysis of microbial cells, isolation, purification and (optionally) encapsulation of the corresponding low molecular weight components of a microbial cell, their metabolites and signaling molecules.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Beloborodova NV, Osipov GA. Small molecules originating from microbes (SMOM) and their role in microbes-host relationship. Microb Ecol Health Dis. 2000;12:12–21.
Dorrestein PC, Mazmanian SK, Knight R. Finding the missing links among metabolites, microbes, and the host. Immunity. 2014;40:824–832. doi:https://doi.org/10.1016/j.immuni.2014.05.015.
Engevik MA, Versalovic J. Biochemical feature of beneficial microbes: foundation for therapeutic microbiology. Microbial Spectr. 2017;5(5). doi:https://doi.org/10.1128/microbiolspec.BAD-0012-2016.
Gilbert JA, Quinn RA, Debelius J, Morton J, Garg N et al. Microbiome-wide association studies link dynamic microbial consortia to disease. Nature. 2016;535:94–103. doi:https://doi.org/10.1038/nature18850.
Holmes E, Li JV, Athanasiou T, Ashrafian H, Nicholson JK. Understanding the role of gut microbiome-host metabolic signal disruption in health and disease. Trends Microbiol. 2011;19:349–359. doi:https://doi.org/10.1016/j.tim.2011.05.006.
Li M, Wang B, Zhang M, Rantalainen M, Wang S et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Avad Sci USA. 2008;105(6):2117–2122. doi:https://doi.org/10.1073/pnas.0712038105.
Nicholson JK, Holmes E, Kinross J, Gibson G, Jia W, Pettersson S. Host-Gut microbiota metabolic interactions. Science. 2012;336(6086):1262–1267. doi:https://doi.org/10.1126/science.1223813.
Nicholson JK, Holmes E, Wilson ID. Gut microorganisms mammalian metabolism and personalized health care. Nat Rev Microbiol. 2005;3:431–438. doi:https://doi.org/10.1038/nrmicro1152.
Shenderov BA. Metabiotics — novel prophylactic technology of diseases associated with microecological imbalance of human being. Journal of Restorative Medicine & Rehabilitation. 2017;4:40–49 (in Russian).
Sonnenburg JL, Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016;535(7610):56–64. doi:https://doi.org/10.1038/nature18846.
Sonnenburg JL, Fischbach MA. Community health care: therapeutic opportunities in the human microbiome. Sci Transl Med. 2011;3(78):78ps12. doi:https://doi.org/10.1126/scitranslmed.3001626.
Vakhitov TYa, Sitkin SI. The concept of superorganism in biology and medicine. Experimental & clinical gastroenterology. 2014;107(7):72–85 (in Russian).
Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci USA. 2009;106(10):3698–3703. doi:https://doi.org/10.1073/pnas.0812874106.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Shenderov, B.A., Sinitsa, A.V., Zakharchenko, M.M., Lang, C. (2020). Prospects in the Field of Intended-Use Metabiotics Creation. In: METABIOTICS. Springer, Cham. https://doi.org/10.1007/978-3-030-34167-1_15
Download citation
DOI: https://doi.org/10.1007/978-3-030-34167-1_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-34166-4
Online ISBN: 978-3-030-34167-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)